• 1. An atomic scale study of defects in Co2FeAl
  Ravi Kumar Yadav,R. Govindaraj Phys. Chem. Chem. Phys., 2020,22, 26876-26886
• 2. An atom efficient route to N-aryl and N-alkyl pyrrolines by transition metal catalysis?
  Supaporn Sawadjoon,Joseph S. M. Samec Org. Biomol. Chem., 2011,9, 2548-2554
• 3. An aqueous ammonia sensor based on an inkjet-printed polyaniline nanoparticle-modified electrode
  Karl Crowley,Eimer O'Malley,Aoife Morrin,Malcolm R. Smyth,Anthony J. Killard Analyst, 2008,133, 391-399
• 4. An approach to 7-aza-1-phosphanorbornane complexes: strain promoted rearrangement of 1-iminylphosphirane complexes and cycloaddition with olefins?
  Yang Xu,Min Wang,Donghui Wei,Rongqiang Tian,Zheng Duan,Fran?ois Mathey Dalton Trans., 2019,48, 5523-5526
• 5. An intensified π-hole in beryllium-doped boron nitride meshes: its determinant role in CO2 conversion into hydrocarbon fuels?
  Luis Miguel Azofra,Douglas R. MacFarlane,Chenghua Sun Chem. Commun., 2016,52, 3548-3551

Recent Advances in the Application of 4-Bromo-2-cyanophenylhydrazine (CAS: 412925-77-0) in Chemical Biology and Pharmaceutical Research

The compound 4-Bromo-2-cyanophenylhydrazine (CAS: 412925-77-0) has recently garnered significant attention in the field of chemical biology and pharmaceutical research due to its versatile applications in drug discovery and development. This hydrazine derivative serves as a crucial intermediate in the synthesis of various bioactive molecules, particularly those targeting enzyme inhibition and receptor modulation. Recent studies have highlighted its role in the design of novel kinase inhibitors and its potential in combating drug-resistant pathogens, making it a compound of high interest for researchers in medicinal chemistry.

In a groundbreaking study published in the Journal of Medicinal Chemistry, researchers utilized 4-Bromo-2-cyanophenylhydrazine as a key building block for the synthesis of selective JAK2 inhibitors. The study demonstrated that the bromo and cyano functional groups on the phenylhydrazine scaffold facilitated efficient binding to the ATP-binding site of JAK2, leading to potent inhibition with minimal off-target effects. This finding opens new avenues for the development of targeted therapies for myeloproliferative disorders and autoimmune diseases, where JAK2 signaling plays a pivotal role.

Another notable application of 4-Bromo-2-cyanophenylhydrazine was reported in the context of antimicrobial drug development. A research team at the University of Cambridge employed this compound to synthesize a series of novel hydrazone derivatives with broad-spectrum activity against multidrug-resistant Gram-positive bacteria. The study, published in ACS Infectious Diseases, revealed that the bromo-cyanophenylhydrazine moiety enhanced the compounds' ability to disrupt bacterial cell wall synthesis, offering a promising strategy to address the growing threat of antibiotic resistance.

Recent advancements in synthetic methodology have also expanded the utility of 4-Bromo-2-cyanophenylhydrazine. A 2023 publication in Organic Letters described a novel palladium-catalyzed cross-coupling reaction that enables efficient functionalization of the bromo group while preserving the reactive hydrazine functionality. This methodological breakthrough has significantly improved the synthetic accessibility of complex hydrazine-based pharmacophores, accelerating structure-activity relationship studies in drug discovery programs.

From a safety and pharmacokinetic perspective, recent preclinical studies have provided valuable insights into the metabolic fate of 4-Bromo-2-cyanophenylhydrazine derivatives. Research published in Drug Metabolism and Disposition characterized the major metabolic pathways of these compounds, identifying cytochrome P450 3A4 as the primary enzyme responsible for their biotransformation. These findings are crucial for optimizing the drug-like properties of molecules derived from this scaffold and minimizing potential toxicity concerns.

Looking forward, the unique structural features of 4-Bromo-2-cyanophenylhydrazine continue to inspire innovative applications in chemical biology. Current research efforts are exploring its use in the development of targeted protein degraders (PROTACs) and covalent inhibitors, leveraging both the reactive hydrazine group and the versatile bromo substituent. As synthetic methodologies advance and our understanding of its biological interactions deepens, this compound is poised to play an increasingly important role in addressing unmet medical needs across multiple therapeutic areas.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)